Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907.

Kristiansen H, Elfving B, Plenge P, Pinborg LH, Gillings N, Knudsen GM.

Synapse. 2005 Dec 15;58(4):249-57.

PMID:
16206185
[PubMed - indexed for MEDLINE]
2.

Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia.

Hurlemann R, Boy C, Meyer PT, Scherk H, Wagner M, Herzog H, Coenen HH, Vogeley K, Falkai P, Zilles K, Maier W, Bauer A.

Anat Embryol (Berl). 2005 Dec;210(5-6):519-23.

PMID:
16187138
[PubMed - indexed for MEDLINE]
3.

Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei.

Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S, Bolwig TG, Knudsen GM.

Int J Neuropsychopharmacol. 2005 Sep;8(3):391-401. Epub 2005 Apr 1.

PMID:
15801987
[PubMed - indexed for MEDLINE]
4.

Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography.

Sheline YI, Mintun MA, Barch DM, Wilkins C, Snyder AZ, Moerlein SM.

Neuropsychopharmacology. 2004 Dec;29(12):2235-41.

PMID:
15367923
[PubMed - indexed for MEDLINE]
Free Article
5.

Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness.

Bailer UF, Price JC, Meltzer CC, Mathis CA, Frank GK, Weissfeld L, McConaha CW, Henry SE, Brooks-Achenbach S, Barbarich NC, Kaye WH.

Neuropsychopharmacology. 2004 Jun;29(6):1143-55.

PMID:
15054474
[PubMed - indexed for MEDLINE]
Free Article
6.

A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables.

Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbøl S, Madsen K, Frøkjaer V, Martiny L, Paulson OB, Knudsen GM.

Neuroimage. 2004 Mar;21(3):1105-13.

PMID:
15006678
[PubMed - indexed for MEDLINE]
7.

5-HT2 receptors.

Leysen JE.

Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):11-26. Review.

PMID:
14965241
[PubMed - indexed for MEDLINE]
8.

5-HT1 receptors.

Lanfumey L, Hamon M.

Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):1-10. Review.

PMID:
14965240
[PubMed - indexed for MEDLINE]
9.

Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography.

Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ.

Biol Psychiatry. 2004 Feb 1;55(3):217-24.

PMID:
14744461
[PubMed - indexed for MEDLINE]
10.

Automatic Synthesis of [(18)F]Altanserin, a Radiopharmaceutical for Positron Emission Tomographic Studies of the Serotonergic Type-2 Receptors.

Monclus M, Van Naemen J, Mulleneers E, Damhaut P, Luxen A, Goldman S.

Clin Positron Imaging. 1998 Mar;1(2):111-116.

PMID:
14516599
[PubMed - as supplied by publisher]
11.

Reduced 5-HT2A receptor binding after recovery from anorexia nervosa.

Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, Skovira K.

Biol Psychiatry. 2002 Nov 1;52(9):896-906.

PMID:
12399143
[PubMed - indexed for MEDLINE]
12.

Greater loss of 5-HT(2A) receptors in midlife than in late life.

Sheline YI, Mintun MA, Moerlein SM, Snyder AZ.

Am J Psychiatry. 2002 Mar;159(3):430-5.

PMID:
11870007
[PubMed - indexed for MEDLINE]
13.

Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans.

Price JC, Lopresti BJ, Meltzer CC, Smith GS, Mason NS, Huang Y, Holt DP, Gunn RN, Mathis CA.

Synapse. 2001 Jul;41(1):11-21.

PMID:
11354009
[PubMed - indexed for MEDLINE]
14.

Analyses of [(18)F] altanserin bolus injection PET data. I: consideration of radiolabeled metabolites in baboons.

Price JC, Lopresti BJ, Mason NS, Holt DP, Huang Y, Mathis CA.

Synapse. 2001 Jul;41(1):1-10.

PMID:
11354008
[PubMed - indexed for MEDLINE]
15.

Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies.

Staley JK, Van Dyck CH, Tan PZ, Al Tikriti M, Ramsby Q, Klump H, Ng C, Garg P, Soufer R, Baldwin RM, Innis RB.

Nucl Med Biol. 2001 Apr;28(3):271-9.

PMID:
11323237
[PubMed - indexed for MEDLINE]
16.

PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders.

Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR, Mulsant BH, Ben-Eliezer D, Lopresti B, DeKosky ST, Reynolds CF 3rd.

Am J Psychiatry. 1999 Dec;156(12):1871-8.

PMID:
10588399
[PubMed - indexed for MEDLINE]
17.

Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent.

Tan PZ, Baldwin RM, Van Dyck CH, Al-Tikriti M, Roth B, Khan N, Charney DS, Innis RB.

Nucl Med Biol. 1999 Aug;26(6):601-8.

PMID:
10587097
[PubMed - indexed for MEDLINE]
18.

A complete remote-control system for reliable preparation of [18F]altanserin.

Tan PZ, Baldwin RM, Soufer R, Garg PK, Charney DS, Innis RB.

Appl Radiat Isot. 1999 May;50(5):923-7.

PMID:
10214711
[PubMed - indexed for MEDLINE]
19.

Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain.

Smith GS, Price JC, Lopresti BJ, Huang Y, Simpson N, Holt D, Mason NS, Meltzer CC, Sweet RA, Nichols T, Sashin D, Mathis CA.

Synapse. 1998 Dec;30(4):380-92.

PMID:
9826230
[PubMed - indexed for MEDLINE]
20.

Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction.

Meltzer CC, Smith G, Price JC, Reynolds CF 3rd, Mathis CA, Greer P, Lopresti B, Mintun MA, Pollock BG, Ben-Eliezer D, Cantwell MN, Kaye W, DeKosky ST.

Brain Res. 1998 Nov 30;813(1):167-71.

PMID:
9824691
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk